These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22161100)

  • 1. [Impact of five genetic polymorphisms on inter-individual variation in warfarin maintenance dose].
    Huang SW; Xiang DK; Wu HL; Chen BL; An BQ; Li GF
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2011 Dec; 28(6):661-5. PubMed ID: 22161100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
    Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
    Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
    Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
    Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
    Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
    Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
    Suriapranata IM; Tjong WY; Wang T; Utama A; Raharjo SB; Yuniadi Y; Tai SS
    BMC Med Genet; 2011 Jun; 12():80. PubMed ID: 21639946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements.
    Cadamuro J; Dieplinger B; Felder T; Kedenko I; Mueller T; Haltmayer M; Patsch W; Oberkofler H
    Eur J Clin Pharmacol; 2010 Mar; 66(3):253-60. PubMed ID: 20020283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
    Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
    Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin.
    Vecsler M; Loebstein R; Almog S; Kurnik D; Goldman B; Halkin H; Gak E
    Thromb Haemost; 2006 Feb; 95(2):205-11. PubMed ID: 16493479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement.
    Herman D; Peternel P; Stegnar M; Breskvar K; Dolzan V
    Thromb Haemost; 2006 May; 95(5):782-7. PubMed ID: 16676068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequency of VKORC1 (C1173T) and CYP2C9 genetic polymorphisms in Egyptians and their influence on warfarin maintenance dose: proposal for a new dosing regimen.
    El Din MS; Amin DG; Ragab SB; Ashour EE; Mohamed MH; Mohamed AM
    Int J Lab Hematol; 2012 Oct; 34(5):517-24. PubMed ID: 22533669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Possible application of pharmacogenomics to warfarin therapy].
    Murata M
    Rinsho Byori; 2011 Jun; 59(6):594-7. PubMed ID: 21815482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.
    Ohno M; Yamamoto A; Ono A; Miura G; Funamoto M; Takemoto Y; Otsu K; Kouno Y; Tanabe T; Masunaga Y; Nonen S; Fujio Y; Azuma J
    Eur J Clin Pharmacol; 2009 Nov; 65(11):1097-103. PubMed ID: 19582440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical relevance of VKORC1 (G-1639A and C1173T) and CYP2C9*3 among patients on warfarin.
    Teh LK; Langmia IM; Fazleen Haslinda MH; Ngow HA; Roziah MJ; Harun R; Zakaria ZA; Salleh MZ
    J Clin Pharm Ther; 2012 Apr; 37(2):232-6. PubMed ID: 21507031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
    Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
    Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Association between CYP2C9 and VKORC1 genetic polymorphism and warfarin dose requirements].
    Yang J; Miao LY; Huang CR; Shen ZY; Jiang WP
    Zhonghua Xin Xue Guan Bing Za Zhi; 2008 Feb; 36(2):137-40. PubMed ID: 19099951
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population].
    Lou Y; Han L; Li Y; Zhang X; Liu Z; Tang M; Yu H; Wang W; Xu J; Liu H; Li Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):367-71. PubMed ID: 24928022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SYBR Green-based real-time PCR assay for detection of VKORC1 and CYP2C9 polymorphisms that modulate warfarin dose requirement.
    Huang SW; Li Q; Zhu SY; Li L; Xiong F; Jia YK; Xu XM
    Clin Chem Lab Med; 2009; 47(1):26-31. PubMed ID: 19117406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP2C9 and vitamin k oxide reductase complex (VKORC)1 polymorphisms on time to determine the warfarin maintenance dose.
    Aomori T; Obayashi K; Fujita Y; Araki T; Nakamura K; Nakamura T; Kurabayashi M; Yamamoto K
    Pharmazie; 2011 Mar; 66(3):222-5. PubMed ID: 21553655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.